Navigation Links
Surveyed Oncologists Expect to Prescribe Provenge to about Half of Their Prostate Cancer Patients if the Vaccine is Approved
Date:7/28/2009

WALTHAM, Mass., July 28 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, if Dendreon's Provenge receives regulatory approval, surveyed oncologists expect to prescribe Provenge to 54 percent of patients with asymptomatic hormone refractory metastatic prostate cancer. Due to the side effects associated with currently available chemotherapy, most oncologists recommend that men who have stopped responding to hormone therapy wait for the development of symptoms before starting chemotherapy.

The new Physician & Payer Forum report entitled Clinician and Payer Attitudes Toward Emerging Cancer Vaccines for Prostate Cancer, Lung Cancer, and Glioma finds that clinicians are willing to prescribe Provenge to patients in the absence of symptoms. The report also finds that three-quarters of surveyed oncologists and urologists consider Provenge a major breakthrough in the treatment of prostate cancer. Additionally, 89 percent of surveyed urologists expect to prescribe Provenge for prostate cancer.

"Treatment rates for advanced prostate cancer will be boosted by an effective vaccine which also carries a benign side effect profile," said Decision Resources Analyst Marcus Hoyle. "Surveyed clinicians indicate they are very encouraged by the fact that, in a Phase III clinical trial, Provenge demonstrated an improvement in median overall survival in prostate cancer patients."

In addition to Provenge, other therapeutic vaccines in development for cancer include Merck KGaA's Stimuvax for non-small-cell lung cancer and Celldex Therapeutics/Pfizer's CDX-110 for glioblastoma multiforme (glioma). Surveyed experts consider both drugs to be the most promising therapeutic vaccines for the treatment of these two diseases, owing to an impressive effect on overall survival
'/>"/>

SOURCE Decision Resources
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. For Treatment of Rheumatoid Arthritis, Surveyed Rheumatologists and Patients Differ In Their Perception of Bristol-Myers Squibbs Orencia
2. For Treatment of Type 2 Diabetes, 89 Percent of Surveyed Endocrinologists Identify a Need for Additional GLP-1 Analogues and 71 Percent Say the Same About DPP-IV Inhibitors
3. For Treatment of Dyslipidemia, Surveyed Physicians are Increasingly Switching Patients to a More Potent Statin Following the ENHANCE and SEAS Trials
4. Availability in Both Intravenous and Oral Formulation is a Leading Drug Attribute Surveyed Physicians Prefer for the Treatment of Urinary Tract Infections in the Hospital Setting
5. Surveyed Psychiatrists and PCPs Expect to Increase Their First-Line Use of SNRIs Over the Next Two Years for the Treatment of Generalized Anxiety Disorder
6. For Alzheimers Disease, Surveyed Neurologists Identify a Therapys Effect on Cognitive Decline as the Attribute That Most Influences Their Prescribing Decisions
7. For Bipolar Depression, Surveyed Experts Indicate That Current and Emerging Therapies Have No Advantage Over Seroquel in Decreasing the Severity of Symptoms
8. Surveyed Experts Indicate That the Combination of Sutent and Taxol Has Advantages Over the Combination of Avastin and Taxol in the Treatment of Metastatic Triple-Negative Breast Cancer
9. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
10. For Atrial Fibrillation, Surveyed Experts Indicate That Multaq, Celivarone and ATI-2042 Have Advantages Over Propafenone in the Maintenance of Normal Sinus Rhythm
11. For Ulcerative Colitis, Surveyed Experts Indicate That Corticosteroids Have Advantages Over Remicade in the Induction of Remission
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/19/2014)... Having been working in the garment industry ... customer needs. According to James, one of the company’s top ... or with high-low skirts that add beauty to them. Chiffon ... LunaDress has unveiled its new selection of 2014 long prom ... brand new items are available in over 20 popular designs. ...
(Date:10/19/2014)... Recently, Fancyflyingfox.com, an innovative company that provides many kinds ... designs of 2014 mother of the bride dresses ... offered with big discounts, up to 70% off. All ... enjoy this special offer. , Owing to the ... one of the leading brands in the global market. ...
(Date:10/19/2014)... (PRWEB) October 19, 2014 Visual ... program has just been released to the public ... online body building and fitness community. The commotion ... of DietsAndFitnessGuides.com's Vin Delmonico prompting an investigative review. ... of hitting what is commonly known as a ...
(Date:10/19/2014)... News) -- New stem cell-based research could improve understanding ... a new study suggests. Scientists used stem cells ... a lab dish. They then transplanted the organoids into ... according to the researchers. "This provides a new ... can cause intestinal failure, from genetic disorders appearing at ...
(Date:10/19/2014)... CHICAGO, OCTOBER 20, 2014 – The U.S. Government ... effectively treat Alzheimer,s disease by 2025. However, a ... says the research milestones in the U.S. Government,s ... broadened in scope, increased in scale, and adequately ... A series of proposals by the workgroup to ...
Breaking Medicine News(10 mins):Health News:2014 Long Prom Dresses From LunaDress Now Available In Over 20 Popular Designs 2Health News:Fancyflyingfox.com Updates Its Website With New Mother Of The Bride Dresses For 2014 2Health News:Visual Impact Frequency Training Review: Rusty Moore's Latest Fitness Guide Released 2Health News:Scientists Grow, Implant Human Intestinal Tissue in Mice 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 2Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 3Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 4Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 5Health News:Scientists say national Alzheimer's plan milestones must be strengthened to meet goal by 2025 6
... on the Indian front has run into rough weather ... Parke-Davis (India). A local court in Hyderabad has ... city. ,The vacation court of the Ranga Reddy ... machinery of Parke-Davis (India) following a petition filed by ...
... has found a new treatment - Vedic vibration technology. ... Vedic Vibration Technology in subjects with arthritis,' revealed that scientists ... in 36 per cent of the patients treated and at ... cent cases. ,The study was recently conducted in Berlin ...
... certain cancers, hepatitis and multiple sclerosis with interferon therapy ... can seriously spoil its quality. Alpha interferon a ... depression. ,A new research now shows that the ... avoid this problem. Almost 50% of people on ...
... Bank, whose website (www.worldbank.org) declares "Our dream is a ... private hospital in Mumbai, India, a move which some ... assistance for projects that will mainly benefit the rich. ... state an International Development Association loan of $134m (89m), ...
... says that women with low risk pregnancies, who live in the ... during pregnancy to 3 - 6 times during pregnancy instead of ... ,However, these women are not more at risk than women ... baby, or have anemia during pregnancy, or spend longer in the ...
... Genetic variations in the HIV strains in Africa make it more ... to researchers. This however does not mean that these drugs will ... to latch on to the protease, which is an enzyme useful ... the drug attaches itself to the protease, then it is easier ...
Cached Medicine News:Health News:The World Bank funds private Hospital in India 2
(Date:10/17/2014)... Conn. , Oct. 17, 2014  UBM Medica ... online community for endocrinologists and other clinicians who treat ... comprehensive coverage on effective use of insulin .  ... eventually require insulin replacement therapy – daily ... for the progressive decline in the function of pancreatic ...
(Date:10/17/2014)...  Ameritox SM , the nation,s leader in medication ... Smith , M.D., as Chief Medical Officer. In this ... resources for healthcare providers, patients and managed care plans. ... a variety of healthcare companies that have provided him ... behavioral health sides of Ameritox,s business. He most recently ...
(Date:10/17/2014)... Oct. 17, 2014   ndd Medical Technologies , ... employing precise ultrasound technology, announced that its EasyOne Pro® ... Healthcare Center , a 140,000 square foot, 44-bed hospital ... hospital serves a large number of Native ... Oklahoma and beyond. A portion of its ...
Breaking Medicine Technology:Endocrinology Network Features Special Coverage on Effective Use of Insulin 2Endocrinology Network Features Special Coverage on Effective Use of Insulin 3Ameritox Appoints New Chief Medical Officer 2EasyOne Pro Mobile Respiratory Testing from ndd Medical Technologies Chosen by Choctaw Nation 2
... Stryker BioZip Suture Anchor is a unique double ... BioZip is made from Poly-L Lactic Acid (PLLA) ... Needles are attached to the suture ends for ... arthroscopic repairs. The trocar tip inserter allows insertion ...
... is an absorbable co-polymer synthesized from ... 18% glycolic acid. Unlike the homopolymers ... poly-L-lactic acid (PLLA) or 100% poly-glycolic ... amorphous (without crystallinity), meaning that its ...
... AnchorSew™ 3 mm is a resorbable repair device ... ArthroSew suturing device to attach soft tissue to ... into a prepared hole in the bone, and ... tissue anchors are made of a resorbable copolymer, ...
... is generally used when anchor size ... anchor is packaged sterile and comes ... and needles. Although pre-drilling is not ... Harpoon®, 1.6mm & 1.8mm drills are ...
Medicine Products: